Login / Signup

Monotherapy versus polytherapy of enoxaparin and hydroxychloroquine for the treatment of COVID-19: A randomized controlled clinical trial.

Amira S A SaidRaghda R S HusseinDoaa Mahmoud KhalilAlzhraa M FahmyAhmed H A HassaneinLamiaa N Abdelaty
Published in: Pharmacy practice (2022)
These findings suggest that Enoxaparin was safe, effective, and well tolerated and has a role in decreasing the progression of the disease and its complications while HCQ did not discover any evidence of extra therapeutic benefits.
Keyphrases
  • venous thromboembolism
  • coronavirus disease
  • sars cov
  • combination therapy
  • risk factors
  • clinical trial
  • respiratory syndrome coronavirus
  • randomized controlled trial
  • study protocol
  • smoking cessation